Duloxetine vs. placebo in patients with painful diabetic neuropathy

Pain

Volumn 116, Issue 1-2, 2005, Pages 109-118

  Goldstein, David J ^a   Lu, Yili ^b   Detke, Michael J ^b,c,d,e   Lee, Thomas C ^b   Iyengar, Smriti ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d MCLEAN HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antidepressant; Cymbalta ; Diabetic neuropathy; Duloxetine; Efficacy; Pain; Safety tolerability

Indexed keywords

DULOXETINE; NORADRENALIN; PLACEBO; SEROTONIN;

ADULT; ANOREXIA; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PAIN ASSESSMENT; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SWEATING; XEROSTOMIA;

AGED; DEMOGRAPHY; DEPRESSION; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PERSONALITY INVENTORY; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME;

EID: 20444464304     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2005.03.029     Document Type: Article

References (25)

1. A.I. Basbaum, and H.L. Fields Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry Annu Rev Neurosci 7 1984 309 338
2. A.T. Beck, N. Epstein, G. Brown, and R.A. Steer An inventory for measuring clinical anxiety: psychometric properties J Consult Clin Psychol 56 1988 893 897
3. A.T. Beck, R.A. Steer, R. Ball, and W. Ranieri Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients J Pers Assess 67 1996 588 597
4. F.M. Clark, and H.K. Proudfit The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception Brain Res 616 1993 200 210
5. C.S. Cleeland, and K.M. Ryan Pain assessment: global use of the Brief Pain Inventory Ann Acad Med Singapore 23 1994 129 138
6. T.J. Coderre, and J. Katz Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain Behav Brain Sci 20 1997 404 419
7. M.J. Detke, Y. Lu, D.J. Goldstein, J.R. Hayes, and M.A. Demitrack Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial J Clin Psychiatry 63 2002 308 315
8. M.J. Detke, Y. Lu, D.J. Goldstein, R.K. McNamara, and M.A. Demitrack Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression J Psychiatr Res 36 2002 383 390
9. H.L. Fields, and A.I. Basbaum Central nervous system mechanisms of pain modulation P.D. Wall R. Melzack Textbook of pain 1999 Churchill Livingstone New York 309 329
10. H.L. Fields, M.M. Heinricher, and P. Mason Neurotransmitters in nociceptive modulatory circuits Annu Rev Neurosci 14 1991 219 245
11. D.J. Goldstein, C. Mallinckrodt, Y. Lu, M. Detke, and M.A. Demitrack Efficacy and safety of duloxetine 120 mg/day in the treatment of depression J Affect Disord 68 2002 108
12. W. Guy ECDEU assessment manual for psychopharmacology, revised 1976 US Department of Health, Education, and Welfare publication (ADM), National Institute of Mental Health Rockville, MD p. 76-338
13. S. Iyengar, A.A. Webster, S.K. Hemrick-Luecke, J.Y. Xu, and R.M.A. Simmons Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine inhibitor in persistent pain models in rats J Pharmacol Exp Ther 311 2004 576 584
14. S. Kapur, T. Mieczkowski, and J.J. Mann Antidepressant medications and the relative risk of suicide attempt and suicide J Am Med Assoc 268 24 1992 3441
15. P. Kind The Euro QoL Instrument: an index of health-related quality of life. Quality of life and pharmacoeconomics in clinical trials 1996 Lippincott-Raven Philadelphia, PA pp. 191-201
16. H.J. McQuay, M. Tramer, B.A. Nye, D. Carroll, P.J. Wiffen, and R.A. Moore A systematic review of antidepressants in neuropathic pain Pain 68 1996 217 227
17. R. Melzack The Short-form McGill Pain Questionnaire Pain 30 1987 191 197
18. C.B. Nemeroff, A.F. Schatzberg, D.J. Goldstein, M.J. Detke, C.H. Mallinckrodt, Y. Lu, and P.V. Tran Duloxetine for the treatment of major depressive disorder Psychopharmacol Bull 36 4 2002 106 132
19. NIMH ECDEU assessment manual for psychopharmacology, revised 1976 National Institute of Mental Health, Psychopharmacology Research Branch Rockville, MD p. 217-222, see also pages 313-331
20. K. Ren, and R. Dubner Descending modulation in persistent pain: an update Pain 100 2002 1 6
21. R.D. Retherford, and M.K. Choe Statistical methods for causal analysis 1993 Wiley New York
22. D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, R. Baker, and G.C. Dunbar The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J Clin Psychiatry 59 1998 22 33
23. S.H. Sindrup, and T.S. Jensen Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action Pain 83 1999 389 400
24. J.E. Ware, K.K. Snow, M. Kosinski, and B. Gandek SF-36 health survey manual and interpretation guide 1993 The Health Institute, New England Medical Center Boston, MA
25. D.T. Wong, and F.P. Bymaster Dual serotonin and noradrenaline uptake inhibitor class of anti-depressants - potential for greater efficacy or just hype? Prog Drug Res 58 2002 169 222